Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "novel transcript, antisense to ARSJ" (ENSG00000310222, also known as LOC107986305) is a computationally annotated antisense RNA that overlaps with the gene encoding arylsulfatase family member J (ARSJ). There are no experimental data linking this transcript to biological functions, disease processes, or pharmacological activity. It is not a recognized therapeutic or diagnostic target. Its designation as "novel" and "antisense" refers only to genomic location and transcriptional orientation, not to validated functional relevance. ARSJ itself, in contrast, is a well-characterized enzyme in the sulfatase gene family and participates in hydrolyzing sulfate esters from macromolecules[1][2][3][5]. However, this antisense transcript has not been explored or described in the scientific literature for molecular function, disease involvement, or therapeutic relevance.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on novel transcript, antisense to ARSJ (LOC107986305).